Related Experiment Video
Updated: May 12, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis
Sonia Berrih-Aknin1, Samia Ragheb, Rozen Le Panse
1Unité Mixte de Recherche-CNRS UMR7215/INSERM U974/UPMC UM76/AIM-Thérapie des Maladies du Muscle Strié, Groupe Hospitalier Pitié-Salpêtrière, 105 Boulevard de l'Hôpital, 75651 Paris, Cedex 13, France. sonia.berrih-aknin@upmc.fr
Abstract:
Myasthenia gravis (MG) is an autoimmune disease mediated by antibodies directed to molecules of the endplate of the neuromuscular junction. B cells play a major role in MG disease since they produce the pathogenic antibodies and therapies targeting B cells are effective. The aim of this article was to review the role of B cells in myasthenia gravis. We will first describe what we know about B cells in this disease and examine the involvement of the B cells in the thymus of MG patients. We will detail the role of factors associated with B-cell function such as BAFF. Finally, we will discuss the effects of therapy targeting B cells.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cell-mediated Immune Responses
Tumor Immunotherapy

